MDCO offered the USPTO what was tantamount to a $60M bribe to get Congress to enact an exemption re the filing deadline, but Congress wouldn’t bite.
So now, the company’s shills on Wall Street are saying that a generic version of Angiomax is exceedingly difficult to manufacture. As you can tell from my prior posts, I don’t buy the argument.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”